These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 1995531)

  • 1. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
    Brown JM; Lemmon MJ
    Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
    Brown JM; Lemmon MJ
    Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
    Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
    Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
    Zeman EM; Lemmon MJ; Brown JM
    Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
    Brown JM; Lemmon MJ
    Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM
    Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ; Menke D; Brown JM
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of agents counteracting hypoxia in fractionated radiation regimes.
    Stern S; Guichard M
    Radiother Oncol; 1996 Nov; 41(2):143-9. PubMed ID: 9004358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
    Zeman EM; Hirst VK; Lemmon MJ; Brown JM
    Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of hypoxia-induced mRNA expressions of HIF-1alpha and osteopontin and in vitro radiosensitization by tirapazamine in human nasopharyngeal carcinoma HNE-1 and CNE-1 cells.
    Xu P; Huang JM; Ren Y; Zha X; Deng BF; Wu JH; Lang JY
    Chin J Cancer; 2010 Feb; 29(2):126-30. PubMed ID: 20109337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
    Minchinton AI; Brown JM
    Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
    Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
    Zhang M; Stevens G
    Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: comparison with tirapazamine.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 2001; 12(8):325-33. PubMed ID: 11589303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reoxygenation and rehypoxiation in the SCCVII mouse tumor.
    Kim IH; Brown JM
    Int J Radiat Oncol Biol Phys; 1994 Jun; 29(3):493-7. PubMed ID: 8005805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targets in radiotherapy.
    Brown JM
    Int J Radiat Oncol Biol Phys; 2001 Feb; 49(2):319-26. PubMed ID: 11173124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-generation 1,2,4-benzotriazine 1,4-di-N-oxide bioreductive anti-tumor agents: pharmacology and activity in vitro and in vivo.
    Minchinton AI; Lemmon MJ; Tracy M; Pollart DJ; Martinez AP; Tosto LM; Brown JM
    Int J Radiat Oncol Biol Phys; 1992; 22(4):701-5. PubMed ID: 1544841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
    Lambin P; Guichard M; Chavaudra N; Malaise EP
    Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic modeling identifies SN30000 and SN29751 as tirapazamine analogues with improved tissue penetration and hypoxic cell killing in tumors.
    Hicks KO; Siim BG; Jaiswal JK; Pruijn FB; Fraser AM; Patel R; Hogg A; Liyanage HD; Dorie MJ; Brown JM; Denny WA; Hay MP; Wilson WR
    Clin Cancer Res; 2010 Oct; 16(20):4946-57. PubMed ID: 20732963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.
    el-Said A; Menke D; Dorie MJ; Brown JM
    Radiat Oncol Investig; 1999; 7(3):163-9. PubMed ID: 10406058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.